Dr Richard Franklin has worked for several major drug companies including Glaxo, Wyeth, Sterling Winthrop, & AstraZeneca. Latterly he was head of New Product Innovation (small molecules) at Shire Pharmaceuticals where he is credited with filing over forty patents on potential new drug products. During his career he has published over sixty scientific papers and was associate editor of the journal, Xenobiotica, for some ten years. He is a past chairman and secretary of the European Drug Metabolism Discussion Group.
Professor Stephen Watson British Heart Foundation Professor in Cardiovascular Sciences and Cellular Pharmacology, University of Birmingham. Professor Watson is head of the Birmingham Platelet Group which undertakes a multidisciplinary approach to the investigation of platelet function in health and disease with a special focus on platelet receptors and their signalling pathways. He was awarded the Order of Phlebology Medal: Australian College of Phlebology Award of Excellence for Basic Science Research in Thrombosis and Haemostasis.